Survey on PD Patients With Depressive Symptoms

August 1, 2014 updated by: Boehringer Ingelheim

BI_Sifrol Tablets Special Drug Use Surveillance(Survey on the Safety and Efficacy in Parkinson's Disease Patients With Depressive Symptoms)

The primary objective of this investigation is to conduct a 12-week prospective survey in PD patients with depressive symptoms treated with BI Sifrol Tablets (hereinafter referred to as this drug) in the routine clinical settings to determine the following items related to the safety and efficacy.

i. Adverse drug reaction symptoms, incidence, and severity ii. Motor capacity during the investigation iii. Depressive symptoms during the investigation

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment (Actual)

1089

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Japan
      • Akashi, Japan
        • Boehringer Ingelheim Investigational Site
      • Akita, Japan
        • Boehringer Ingelheim Investigational Site 1
      • Akita, Japan
        • Boehringer Ingelheim Investigational Site 2
      • Asahikawa, Japan
        • Boehringer Ingelheim Investigational Site
      • Ashikaga, Japan
        • Boehringer Ingelheim Investigational Site
      • Awaji, Japan
        • Boehringer Ingelheim Investigational Site
      • Chitose, Japan
        • Boehringer Ingelheim Investigational Site
      • Chuo, Japan
        • Boehringer Ingelheim Investigational Site
      • Fuchu, Japan
        • Boehringer Ingelheim Investigational Site 1
      • Fuchu, Japan
        • Boehringer Ingelheim Investigational Site 2
      • Fuefuki, Japan
        • Boehringer Ingelheim Investigational Site
      • Fuehuki, Japan
        • Boehringer Ingelheim Investigational Site
      • Fujioka, Japan
        • Boehringer Ingelheim Investigational Site
      • Fujisaki, Japan
        • Boehringer Ingelheim Investigational Site
      • Fujisawa, Japan
        • Boehringer Ingelheim Investigational Site
      • Fukaya, Japan
        • Boehringer Ingelheim Investigational Site
      • Fukuoka, Japan
        • Boehringer Ingelheim Investigational Site 1
      • Fukuoka, Japan
        • Boehringer Ingelheim Investigational Site 2
      • Fukuoka, Japan
        • Boehringer Ingelheim Investigational Site 3
      • Fukuoka, Japan
        • Boehringer Ingelheim Investigational Site 4
      • Fukuoka, Japan
        • Boehringer Ingelheim Investigational Site 5
      • Fukushima, Japan
        • Boehringer Ingelheim Investigational Site 1
      • Fukushima, Japan
        • Boehringer Ingelheim Investigational Site 2
      • Funabashi, Japan
        • Boehringer Ingelheim Investigational Site
      • Gifu, Japan
        • Boehringer Ingelheim Investigational Site 1
      • Gifu, Japan
        • Boehringer Ingelheim Investigational Site 2
      • Habikino, Japan
        • Boehringer Ingelheim Investigational Site
      • Hachioji, Japan
        • Boehringer Ingelheim Investigational Site
      • Hamamatsu, Japan
        • Boehringer Ingelheim Investigational Site 1
      • Hamamatsu, Japan
        • Boehringer Ingelheim Investigational Site 2
      • Hamamatsu, Japan
        • Boehringer Ingelheim Investigational Site 3
      • Hamamatsu, Japan
        • Boehringer Ingelheim Investigational Site 4
      • Hamamatsu, Japan
        • Boehringer Ingelheim Investigational Site 5
      • Hanamaki, Japan
        • Boehringer Ingelheim Investigational Site
      • Hayashima, Japan
        • Boehringer Ingelheim Investigational Site
      • Higashiosaka, Japan
        • Boehringer Ingelheim Investigational Site 1
      • Higashiosaka, Japan
        • Boehringer Ingelheim Investigational Site 2
      • Himeji, Japan
        • Boehringer Ingelheim Investigational Site
      • Hirakata, Japan
        • Boehringer Ingelheim Investigational Site
      • Hirishima, Japan
        • Boehringer Ingelheim Investigational Site
      • Hirosaki, Japan
        • Boehringer Ingelheim Investigational Site
      • Ibaragi, Japan
        • Boehringer Ingelheim Investigational Site
      • Iizuka, Japan
        • Boehringer Ingelheim Investigational Site
      • Inag, Japan
        • Boehringer Ingelheim Investigational Site
      • Irima, Japan
        • Boehringer Ingelheim Investigational Site
      • Isahaya, Japan
        • Boehringer Ingelheim Investigational Site
      • Iwaki, Japan
        • Boehringer Ingelheim Investigational Site
      • Iwamizawa, Japan
        • Boehringer Ingelheim Investigational Site
      • Iwata, Japan
        • Boehringer Ingelheim Investigational Site
      • Jyoetsu, Japan
        • Boehringer Ingelheim Investigational Site 1
      • Jyoetsu, Japan
        • Boehringer Ingelheim Investigational Site 2
      • Jyoyo, Japan
        • Boehringer Ingelheim Investigational Site
      • Kagoshima, Japan
        • Boehringer Ingelheim Investigational Site 1
      • Kagoshima, Japan
        • Boehringer Ingelheim Investigational Site 2
      • Kagoshima, Japan
        • Boehringer Ingelheim Investigational Site 3
      • Kahoku, Japan
        • Boehringer Ingelheim Investigational Site
      • Kamakura, Japan
        • Boehringer Ingelheim Investigational Site
      • Kanazawa, Japan
        • Boehringer Ingelheim Investigational Site 1
      • Kanazawa, Japan
        • Boehringer Ingelheim Investigational Site 2
      • Kanoya, Japan
        • Boehringer Ingelheim Investigational Site 1
      • Kanoya, Japan
        • Boehringer Ingelheim Investigational Site 2
      • Kashihara, Japan
        • Boehringer Ingelheim Investigational Site 1
      • Kashihara, Japan
        • Boehringer Ingelheim Investigational Site 2
      • Kasuga, Japan
        • Boehringer Ingelheim Investigational Site
      • Kawagchi, Japan
        • Boehringer Ingelheim Investigational Site
      • Kawaguchi, Japan
        • Boehringer Ingelheim Investigational Site
      • Kawasaki, Japan
        • Boehringer Ingelheim Investigational Site 1
      • Kawasaki, Japan
        • Boehringer Ingelheim Investigational Site 2
      • Kitakami, Japan
        • Boehringer Ingelheim Investigational Site
      • Kiyose, Japan
        • Boehringer Ingelheim Investigational Site 1
      • Kiyose, Japan
        • Boehringer Ingelheim Investigational Site 2
      • Kodaira, Japan
        • Boehringer Ingelheim Investigational Site
      • Kofu, Japan
        • Boehringer Ingelheim Investigational Site
      • Koga, Japan
        • Boehringer Ingelheim Investigational Site
      • Komae, Japan
        • Boehringer Ingelheim Investigational Site
      • Komatsu, Japan
        • Boehringer Ingelheim Investigational Site
      • Komatsushima, Japan
        • Boehringer Ingelheim Investigational Site
      • Koriyama, Japan
        • Boehringer Ingelheim Investigational Site 1
      • Koriyama, Japan
        • Boehringer Ingelheim Investigational Site 2
      • Koshigaya, Japan
        • Boehringer Ingelheim Investigational Site
      • Kumamoto, Japan
        • Boehringer Ingelheim Investigational Site 1
      • Kumamoto, Japan
        • Boehringer Ingelheim Investigational Site 2
      • Kumamoto, Japan
        • Boehringer Ingelheim Investigational Site 3
      • Kure, Japan
        • Boehringer Ingelheim Investigational Site
      • Kusatsu, Japan
        • Boehringer Ingelheim Investigational Site
      • Kyoto, Japan
        • Boehringer Ingelheim Investigational Site 1
      • Kyoto, Japan
        • Boehringer Ingelheim Investigational Site 2
      • Kyoto, Japan
        • Boehringer Ingelheim Investigational Site 3
      • Kyoto, Japan
        • Boehringer Ingelheim Investigational Site 4
      • Maebashi, Japan
        • Boehringer Ingelheim Investigational Site
      • Matsudo, Japan
        • Boehringer Ingelheim Investigational Site
      • Matsumoto, Japan
        • Boehringer Ingelheim Investigational Site
      • Mibu, Japan
        • Boehringer Ingelheim Investigational Site
      • Mihara, Japan
        • Boehringer Ingelheim Investigational Site
      • Mihoro, Japan
        • Boehringer Ingelheim Investigational Site
      • Miriyama, Japan
        • Boehringer Ingelheim Investigational Site
      • Misato, Japan
        • Boehringer Ingelheim Investigational Site
      • Miyako, Japan
        • Boehringer Ingelheim Investigational Site
      • Miyazaki, Japan
        • Boehringer Ingelheim Investigational Site 1
      • Miyazaki, Japan
        • Boehringer Ingelheim Investigational Site 2
      • Moriguchi, Japan
        • Boehringer Ingelheim Investigational Site
      • Morioka, Japan
        • Boehringer Ingelheim Investigational Site 1
      • Morioka, Japan
        • Boehringer Ingelheim Investigational Site 2
      • Moriya, Japan
        • Boehringer Ingelheim Investigational Site
      • Musashino, Japan
        • Boehringer Ingelheim Investigational Site
      • Nagano, Japan
        • Boehringer Ingelheim Investigational Site
      • Nagaoka, Japan
        • Boehringer Ingelheim Investigational Site
      • Nagaokakyo, Japan
        • Boehringer Ingelheim Investigational Site
      • Nagoya, Japan
        • Boehringer Ingelheim Investigational Site 1
      • Nagoya, Japan
        • Boehringer Ingelheim Investigational Site 2
      • Nagoya, Japan
        • Boehringer Ingelheim Investigational Site 3
      • Nagoya, Japan
        • Boehringer Ingelheim Investigational Site 4
      • Nara, Japan
        • Boehringer Ingelheim Investigational Site 1
      • Nara, Japan
        • Boehringer Ingelheim Investigational Site 2
      • Narashino, Japan
        • Boehringer Ingelheim Investigational Site
      • Narita, Japan
        • Boehringer Ingelheim Investigational Site
      • Naruto, Japan
        • Boehringer Ingelheim Investigational Site
      • Nasushiobara, Japan
        • Boehringer Ingelheim Investigational Site
      • Nichinan, Japan
        • Boehringer Ingelheim Investigational Site
      • Ninohe, Japan
        • Boehringer Ingelheim Investigational Site
      • Nishinomiya, Japan
        • Boehringer Ingelheim Investigational Site
      • Nishitokyo, Japan
        • Boehringer Ingelheim Investigational Site
      • Ogaki, Japan
        • Boehringer Ingelheim Investigational Site
      • Oiso, Japan
        • Boehringer Ingelheim Investigational Site
      • Oita, Japan
        • Boehringer Ingelheim Investigational Site 1
      • Oita, Japan
        • Boehringer Ingelheim Investigational Site 2
      • Oita, Japan
        • Boehringer Ingelheim Investigational Site 3
      • Okaya, Japan
        • Boehringer Ingelheim Investigational Site
      • Okayama, Japan
        • Boehringer Ingelheim Investigational Site 1
      • Okayama, Japan
        • Boehringer Ingelheim Investigational Site 2
      • Okazaki, Japan
        • Boehringer Ingelheim Investigational Site
      • Okinawa, Japan
        • Boehringer Ingelheim Investigational Site
      • Omura, Japan
        • Boehringer Ingelheim Investigational Site
      • Omuta, Japan
        • Boehringer Ingelheim Investigational Site
      • Onojyo, Japan
        • Boehringer Ingelheim Investigational Site
      • Osaka, Japan
        • Boehringer Ingelheim Investigational Site 1
      • Osaka, Japan
        • Boehringer Ingelheim Investigational Site 2
      • Osaka, Japan
        • Boehringer Ingelheim Investigational Site 3
      • Osaka, Japan
        • Boehringer Ingelheim Investigational Site 4
      • Osaka, Japan
        • Boehringer Ingelheim Investigational Site 5
      • Osaka, Japan
        • Boehringer Ingelheim Investigational Site 6
      • Ota, Japan
        • Boehringer Ingelheim Investigational Site
      • Otake, Japan
        • Boehringer Ingelheim Investigational Site
      • Otsu, Japan
        • Boehringer Ingelheim Investigational Site
      • Ryugasaki, Japan
        • Boehringer Ingelheim Investigational Site
      • Saeki, Japan
        • Boehringer Ingelheim Investigational Site
      • Saga, Japan
        • Boehringer Ingelheim Investigational Site
      • Sagamihara, Japan
        • Boehringer Ingelheim Investigational Site 1
      • Sagamihara, Japan
        • Boehringer Ingelheim Investigational Site 2
      • Sagamihara, Japan
        • Boehringer Ingelheim Investigational Site 3
      • Saijyo, Japan
        • Boehringer Ingelheim Investigational Site
      • Saitama, Japan
        • Boehringer Ingelheim Investigational Site
      • Sakai, Japan
        • Boehringer Ingelheim Investigational Site 1
      • Sakai, Japan
        • Boehringer Ingelheim Investigational Site 2
      • Sapporo, Japan
        • Boehringer Ingelheim Investigational Site 3
      • Sapporo, Japan
        • Boehringer Ingelheim Investigational Site 4
      • Sapporo, Japan
        • Boehringer Ingelheim Investigational Site 5
      • Sapporo, Japan
        • Boehringer Ingelheim Investigational Site 6
      • Sapporo, Japan
        • Boehringer Ingelheim Investigational Site 8
      • Sapporo, Japan
        • Boehringer Ingelheim Investigational Site 9
      • Sapporo, Japan
        • Boehringer Ingelheim Investigational Site 7
      • Sapporo, Japan
        • Boehringer Ingelheim Investigational Site 1
      • Sapporo, Japan
        • Boehringer Ingelheim Investigational Site 2
      • Sekigahara, Japan
        • Boehringer Ingelheim Investigational Site
      • Sendai, Japan
        • Boehringer Ingelheim Investigational Site 1
      • Sendai, Japan
        • Boehringer Ingelheim Investigational Site 2
      • Shimoda, Japan
        • Boehringer Ingelheim Investigational Site
      • Shimotsuke, Japan
        • Boehringer Ingelheim Investigational Site 1
      • Shimotsuke, Japan
        • Boehringer Ingelheim Investigational Site 2
      • Shinngu, Japan
        • Boehringer Ingelheim Investigational Site
      • Shiroishi, Japan
        • Boehringer Ingelheim Investigational Site
      • Shizuoka, Japan
        • Boehringer Ingelheim Investigational Site 1
      • Shizuoka, Japan
        • Boehringer Ingelheim Investigational Site 2
      • Showajima, Japan
        • Boehringer Ingelheim Investigational Site
      • Suita, Japan
        • Boehringer Ingelheim Investigational Site 1
      • Suita, Japan
        • Boehringer Ingelheim Investigational Site 2
      • Susono, Japan
        • Boehringer Ingelheim Investigational Site
      • Suzuka, Japan
        • Boehringer Ingelheim Investigational Site
      • Takaoka, Japan
        • Boehringer Ingelheim Investigational Site 1
      • Takaoka, Japan
        • Boehringer Ingelheim Investigational Site 2
      • Takatsuki, Japan
        • Boehringer Ingelheim Investigational Site
      • Tarimizu, Japan
        • Boehringer Ingelheim Investigational Site
      • Togitsu, Japan
        • Boehringer Ingelheim Investigational Site
      • Tokoname, Japan
        • Boehringer Ingelheim Investigational Site
      • Tokushima, Japan
        • Boehringer Ingelheim Investigational Site
      • Tokyo Arakawa-ku, Japan
        • Boehringer Ingelheim Investigational Site
      • Tokyo Bunkyo-ku, Japan
        • Boehringer Ingelheim Investigational Site
      • Tokyo Chuo-ku, Japan
        • Boehringer Ingelheim Investigational Site 1
      • Tokyo Chuo-ku, Japan
        • Boehringer Ingelheim Investigational Site 2
      • Tokyo Daito-ku, Japan
        • Boehringer Ingelheim Investigational Site
      • Tokyo Koto-ku, Japan
        • Boehringer Ingelheim Investigational Site
      • Tokyo Meguro-ku, Japan
        • Boehringer Ingelheim Investigational Site 1
      • Tokyo Meguro-ku, Japan
        • Boehringer Ingelheim Investigational Site 2
      • Tokyo Minato-ku, Japan
        • Boehringer Ingelheim Investigational Site 1
      • Tokyo Minato-ku, Japan
        • Boehringer Ingelheim Investigational Site 2
      • Tokyo Minato-ku, Japan
        • Boehringer Ingelheim Investigational Site 3
      • Tokyo Nakano-ku, Japan
        • Boehringer Ingelheim Investigational Site
      • Tokyo Nerima-ku, Japan
        • Boehringer Ingelheim Investigational Site
      • Tokyo Ota-ku, Japan
        • Boehringer Ingelheim Investigational Site 1
      • Tokyo Ota-ku, Japan
        • Boehringer Ingelheim Investigational Site 2
      • Tokyo Setagaya, Japan
        • Boehringer Ingelheim Investigational Site
      • Tokyo Setagaya-ku, Japan
        • Boehringer Ingelheim Investigational Site
      • Tokyo Shibuya-ku, Japan
        • Boehringer Ingelheim Investigational Site
      • Tokyo Shinagawa-ku, Japan
        • Boehringer Ingelheim Investigational Site
      • Tokyo Shinjyuku-ku, Japan
        • Boehringer Ingelheim Investigational Site 1
      • Tokyo Shinjyuku-ku, Japan
        • Boehringer Ingelheim Investigational Site 2
      • Tokyo Shinjyuku-ku, Japan
        • Boehringer Ingelheim Investigational Site 3
      • Tokyo Sibuya-ku, Japan
        • Boehringer Ingelheim Investigational Site
      • Tokyo Toshima-ku, Japan
        • Boehringer Ingelheim Investigational Site
      • Tokyo-Edogawa-ku, Japan
        • Boehringer Ingelheim Investigational Site
      • Tokyo-Itabashi-ku, Japan
        • Boehringer Ingelheim Investigational Site
      • Toride, Japan
        • Boehringer Ingelheim Investigational Site
      • Tosu, Japan
        • Boehringer Ingelheim Investigational Site
      • Toyama, Japan
        • Boehringer Ingelheim Investigational Site 1
      • Toyama, Japan
        • Boehringer Ingelheim Investigational Site 2
      • Toyama, Japan
        • Boehringer Ingelheim Investigational Site 3
      • Toyohashi, Japan
        • Boehringer Ingelheim Investigational Site
      • Toyokawa, Japan
        • Boehringer Ingelheim Investigational Site
      • Toyonaka, Japan
        • Boehringer Ingelheim Investigational Site
      • Ube, Japan
        • Boehringer Ingelheim Investigational Site
      • Uchinada, Japan
        • Boehringer Ingelheim Investigational Site
      • Ueda, Japan
        • Boehringer Ingelheim Investigational Site
      • Ushiku, Japan
        • Boehringer Ingelheim Investigational Site
      • Utsunomiya, Japan
        • Boehringer Ingelheim Investigational Site 1
      • Utsunomiya, Japan
        • Boehringer Ingelheim Investigational Site 2
      • Wakayama, Japan
        • Boehringer Ingelheim Investigational Site
      • Yachiyo, Japan
        • Boehringer Ingelheim Investigational Site 1
      • Yachiyo, Japan
        • Boehringer Ingelheim Investigational Site 2
      • Yachiyo, Japan
        • Boehringer Ingelheim Investigational Site 3
      • Yamanashi, Japan
        • Boehringer Ingelheim Investigational Site
      • Yanago, Japan
        • Boehringer Ingelheim Investigational Site
      • Yoichi, Japan
        • Boehringer Ingelheim Investigational Site
      • Yokohama, Japan
        • Boehringer Ingelheim Investigational Site 1
      • Yokohama, Japan
        • Boehringer Ingelheim Investigational Site 2
      • Yokohama, Japan
        • Boehringer Ingelheim Investigational Site 3
      • Yokohama, Japan
        • Boehringer Ingelheim Investigational Site 4
      • Yokosuka, Japan
        • Boehringer Ingelheim Investigational Site
      • Yoshinogawa, Japan
        • Boehringer Ingelheim Investigational Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

PD patients with depressive symptoms

Description

Inclusion criteria:

**PD patients with depressive symptoms Patients who have not received pramipexole hydrochloride hydrate preparations within 1 month before survey entrance.

Exclusion criteria:

  • PD patients with the past history of suicidal attempt, suicidal ideation or tendency
  • PD patients with suicidal ideation
  • PD patients with the past history of suicidal tendency

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
BI-Sifrol® Tablets (Pramipexole)
BI-Sifrol® Tablets, pramipexole dose: 0.125 mg, 0.5 mg, No reference therapy

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Percentage of Participants With Adverse Events, Adverse Drug Reactions, and Serious Adverse Events
Time Frame: for 12 weeks
The aim of this Post Marketing Surveillance (PMS) was to obtain safety data with treatment of pramipexole in Parkinson's disease patients with depressive symptoms. The percentage of participants with adverse events, adverse drug reactions, and serious adverse events are presented.
for 12 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Clinical Global Impression of Improvement
Time Frame: for 12 weeks after initiation of the treatment
Investigators evaluation of the Parkinson's disease (PD) symptoms on the Clinical Global Impression (CGI) with 5 categories (very much improved, much improved, minimally improved, no effect, and unassessable).
for 12 weeks after initiation of the treatment
Mean Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part III Total Score
Time Frame: Baseline and after 12 weeks (or at the time of discontinuation)
Part III of the UPDRS contains the clinician-scored motor evaluation, and includes 14 individual items each scored from 0 (Normal) to 4 (Extreme dysfunction). The total score ranged from 0 to 56. A negative change in the Part III total score indicates improvement.
Baseline and after 12 weeks (or at the time of discontinuation)
Mean Change From Baseline in Beck's Depression Inventory (BDI) Total Score
Time Frame: Baseline and after 12 weeks (or at the time of discontinuation)
The degree of severity in depressive state are scored between 0-63 in BDI. A decrease in the score means improvement.
Baseline and after 12 weeks (or at the time of discontinuation)
Mean Change From Baseline in UPDRS (Unified Parkinson's Disease Rating Scale) Part I Item 3 Score
Time Frame: Baseline and after 12 weeks (or at the time of discontinuation)
Unified Parkinson's Disease Rating Scale Part I Item 3 assesses the participant for symptoms of depression. Item 3 scores range from 0 (None) to 4 (Sustained depression with suicidal thoughts or intent). A higher score indicates more severe depression symptoms. A negative change in the item 3 score indicates improvement.
Baseline and after 12 weeks (or at the time of discontinuation)
Mean Change From Baseline in Modified Hoehn & Yahr Rating Scale
Time Frame: After 12 weeks or at the time of discontinuation
This scale is an investigator-completed assessment of the degree of complications arising from Parkinson's disease. The scale ranges from 0 (No signs) to 5 (Bedridden). A negative change in the Yahr rating scale indicates improvement.
After 12 weeks or at the time of discontinuation

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Boehringer Ingelheim

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2007

Primary Completion (Actual)

August 1, 2009

Study Registration Dates

First Submitted

January 31, 2008

First Submitted That Met QC Criteria

February 12, 2008

First Posted (Estimate)

February 13, 2008

Study Record Updates

Last Update Posted (Estimate)

August 6, 2014

Last Update Submitted That Met QC Criteria

August 1, 2014

Last Verified

August 1, 2014

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 248.635

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Parkinson Disease

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Moldova

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe